EWING, N.J., May 12, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc., (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it has entered into a loan agreement with Hercules Technology Growth Capital, Inc. (NYSE:HTGC), a specialty finance company that provides customized debt financing to companies in life sciences and technology-related markets. Hercules will provide Celator with access to a term loan of up to $15 million.
Help employers find you! Check out all the jobs and post your resume.